Denali Therapeutics Inc. Finance Lease, Liability
Denali Therapeutics Inc. (DNLI) had Finance Lease, Liability of $5.62 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:FinanceLeaseLiability · last filed 2026-02-26
- 2025-12-31: Finance Lease, Liability $5.62M.
- 2025-09-30: Finance Lease, Liability $5.63M.
- 2025-06-30: Finance Lease, Liability $6.99M.
- 2025-03-31: Finance Lease, Liability $8.54M.
| Period end | Finance Lease, Liability |
|---|---|
| 2025-12-31 | $5.62M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.63M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $6.99M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $8.54M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $9.34M 10-K · filed 2025-02-27 |
| 2024-09-30 | $5.68M 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |